raloxifene hydrochloride has been researched along with transforming growth factor alpha in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Catherino, WH; Jordan, VC; Levenson, AS | 1 |
| Jordan, VC; Levenson, AS | 1 |
| Jordan, VC | 1 |
| Bentrem, DJ; Jordan, VC; Liu, H; MacGregor Schafer, J; Zapf, JW | 1 |
| Deb Los Reyes, A; Jordan, VC; Lee, ES; Liu, H; Zapf, JW | 1 |
| Bentrem, DJ; Jordan, VC; Liu, H; Loweth, JA; McKian, KP; Park, WC; Reyes, Ade L; Schafer, JM; Zapf, JW | 1 |
1 review(s) available for raloxifene hydrochloride and transforming growth factor alpha
| Article | Year |
|---|---|
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms | 1998 |
5 other study(ies) available for raloxifene hydrochloride and transforming growth factor alpha
| Article | Year |
|---|---|
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1997 |
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Topics: Aspartic Acid; Blotting, Northern; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Mutagenesis, Site-Directed; Piperidines; Point Mutation; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1998 |
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
Topics: Allosteric Regulation; Amino Acid Substitution; Aspartic Acid; Binding Sites; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Glycine; Humans; Kinetics; Ligands; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Tertiary; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2000 |
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Topics: Allosteric Regulation; Breast Neoplasms; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Humans; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2001 |
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Nuclear Receptor Coactivator 2; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Transcription Factors; Transfection; Transforming Growth Factor alpha; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |